CUBT (Curative Biotechnology) Cash per Share: $0.02 (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Curative Biotechnology Cash per Share?

Curative Biotechnology CUBT +8.70% Cash per Share is $0.02 as of Mar. 2023.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Curative Biotechnology's Cash per Share for the quarter that ended in Mar. 2023 was $0.02.


Curative Biotechnology  (OTCPK:CUBT) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


Curative Biotechnology Cash per Share Related Terms


Curative Biotechnology Cash per Share Historical Data

* Premium members only.

The historical data trend for Curative Biotechnology's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biotechnology Cash per Share Chart

Curative Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash per Share
Get a 7-Day Free Trial 0.00 0.00 0.07 0.19 0.02

Curative Biotechnology Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.04 0.00 0.02 0.02

Curative Biotechnology Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Curative Biotechnology's Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Curative Biotechnology's Cash per Share for the quarter that ended in Mar. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $0.02 mean?
Curative Biotechnology (CUBT) has a Cash per Share of $0.02 as of Mar. 2023. Cash per share is the per-share value of a company's available cash. View historical data for Curative Biotechnology and its competitors.
Is Curative Biotechnology's Cash per Share too high?
Curative Biotechnology's current Cash per Share is $0.02.
How does Curative Biotechnology's Cash per Share compare to ORGS and SNSE?
Curative Biotechnology's Cash per Share of $0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Curative Biotechnology and its competitors. Curative Biotechnology's current Cash per Share is $0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biotechnology stock overvalued right now?
Curative Biotechnology (CUBT) has a current Cash per Share of $0.02. The current Cash per Share is $0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Curative Biotechnology (CUBT), the current Cash per Share is $0.02 as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biotechnology Business Description

Address 3801 PGA Boulevard, Suite 600, Palm Beach Gardens, FL, USA, 33410
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform.